Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors-Reference-Cited by-同舟云学术

Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors

Published:2023-02-02 Issue:4 Volume:66 Page:2386-2395
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Blum Andreas¹^ORCID,Dorsch Dieter¹,Linde Nina¹,Brandstetter Susanne¹,Buchstaller Hans-Peter¹^ORCID,Busch Michael¹,Glaser Nina¹,Grädler Ulrich¹,Ruff Aaron¹,Petersson Carl¹,Schieferstein Hanno¹,Sherbetjian Eva¹,Esdar Christina¹

Affiliation:

1. Merck Healthcare KGaA, Frankfurter Str. 250, 64293Darmstadt, Germany

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c00851

Reference24 articles.

1. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease

2. Current clinical management of gastrointestinal stromal tumors

3. Stem Cell Factor Receptor/c-Kit: From Basic Science to Clinical Implications

4. Antonescu, C. R. The GIST Paradigm: Lessons for Other Kinase-Driven Cancers; John Wiley and Sons Ltd: 2011; Vol. 223, pp 252–262.

5. Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem;Expert Opinion on Investigational Drugs;2024-02-14

2. Imidazopyridine-based kinase inhibitors as potential anticancer agents: A review;Bioorganic Chemistry;2023-11

3. Small Molecule c-KIT Inhibitors for the Treatment of Gastrointestinal Stromal Tumors: A Review on Synthesis, Design Strategies, and Structure–Activity Relationship (SAR);International Journal of Molecular Sciences;2023-05-29

4. Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line–Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST);Clinical Cancer Research;2023-05-24